<DOC>
	<DOCNO>NCT00101400</DOCNO>
	<brief_summary>The purpose study evaluate anti-cancer activity safety BAY43-9006 ( Sorafenib ) patient , suffer advanced breast tumour , spread organ body despite treatment patient receive far .</brief_summary>
	<brief_title>BAY43-9006 - Phase II Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age &gt; 18 year Women prior histologically document diagnosis breast cancer Subjects metastatic disease already receive fail least one chemotherapy regimen metastatic disease , ER/PgR +ve , fail least adjuvant hormonal therapy Subjects trastuzumab treatment indicate , longer effective refused subject Four week since last cytotoxic chemotherapy clear evidence progression hormonal therapy Subjects least one measurable lesion CT ( Computed Tomography ) scan MRI ( Magnetic Resonance Imaging ) accord modify WHO Tumour Response Criteria Subjects Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Adequate bone marrow , liver renal function assess follow laboratory evaluation : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count = 100,000/Âµl Total bilirubin =1.5 x upper limit normal . Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) = 2.5 x upper limit normal ( =5 x upper limit normal subject liver involvement cancer ) Amylase lipase = 1.5 x upper limit normal Serum creatinine = 3.0 x upper limit normal Prothrombin Time ( PT ) International Normalized Ratio ( INR ) Partial Thromboplastin Time ( PTT ) &lt; 1.5 x upper limit normal ( subject receive anticoagulation treatment agent warfarin heparin allow participate provide evidence underlying abnormality parameter exist ) Subjects give write informed consent prior study specific screen procedure understand subject right withdraw study time , without prejudice Life expectancy least 12 week Signed informed consent must obtain prior study specific procedure Previous malignancy ( except cervical carcinoma situ , adequately treat basal cell carcinoma , superficial bladder tumour [ Ta , Tis T1 ] malignancy curatively treat &gt; 2 year prior entry ) Congestive heart failure &gt; New York Heart Association ( NYHA ) Class II Cardiac arrhythmia require antiarrhythmic ( exclude beta blocker digoxin ) Active coronary artery disease ischaemia Active clinically serious bacterial fungal infection ( &gt; grade 2 National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) , Version 3 ) Known History Human Immunodeficiency Virus ( HIV ) infection chronic hepatitis B C Metastatic brain meningeal tumor unless subject &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry . Also patient must undergo acute steroid therapy taper ( chronic steroid therapy acceptable provide dose stable 1 month prior follow screen radiographic study ) Subjects seizure disorder require medication ( steroid antiepileptic ) History organ allograft Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result Known suspect allergy investigational agent Any condition unstable could jeopardize safety subject his/her compliance study . Pregnant breastfeed subject . Women childbearing potential must negative pregnancy test perform within seven day prior start study drug . Women enrol trial must use adequate barrier birth control measure course trial . Excluded therapy include : Anticancer chemotherapy , hormonal therapy immunotherapy study within 4 week study entry . Mytomicin nitroureas give within 6 week study entry Significant surgery within 4 week prior start study drug Any bone marrow transplant stem cell rescue within 4 month start study drug Radiotherapy study within 3 week start drug Use biologic response modifier , GranulocyteColony Stimulating Factor ( GCSF ) , within 3 week study entry Investigational drug therapy outside trial within 30 day prior start study drug Concomitant treatment ketoconazole , itraconazole , ritonavir , use grapefruit juice Prior use RafKinase Inhibitors ( RKI ) , Methyl Ethyl Ketone ( MEK ) farnesyl transferase inhibitor Concomitant treatment use St. John 's Wort Prior use bevacizumab drug target Vascular Endothelial Growth Factor ( VEGF ) /VEGF receptor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Cancer</keyword>
</DOC>